Other Publications

Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study The BCI Registry study is an ongoing, prospective, large-scale, multicenter study investigating long-term clinical outcomes, decision impact, and medication adherence in patients with HR-positive early-stage breast cancer receiving BCI testing as part of routine clinical care. This study aimed to assess the impact of BCI on clinical decision-making regarding EET based on the first 1,000 patients enrolled in the BCI Registry study out of an enrollment goal of 3,000.1 Available free from Journal of the National Comprehensive Cancer Network. 1. Sanft TB et al. J Natl Compr Canc Netw. 2024; 22(2):99-107.

Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer Patients with early-stage, hormone receptor–positive breast cancer with favorable clinicopathologic features are often not recommended for extended endocrine therapy. However, even patients with T1N0 disease remain at significant risk of distant recurrence up to 15 years following 5 years of endocrine therapy, highlighting the need for further stratification based on individualized risk to select patients for extended endocrine therapy. In this study, the incremental utility of genomic classification to stratify clinically low-risk patients for late distant recurrence was evaluated using the Breast Cancer Index.1 Available free from Nature Portfolio Journal. 1.Schroeder B et al. NPJ Breast Cancer. 2017;3(28).